Penn Medicine Provider
Hematology
Sunita D Nasta, MD
She/Her/Hers
5.0
(823)
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Perelman 4th Floor West
Make an appointmentCall 215-615-5858

About me

  • Chair, Clinical Trials Review Monitoring Committee
  • Committee Chair, Penn Institutional Review Board
  • Section Chief, Lymphoma, Hematology-Oncology
  • Professor of Clinical Medicine (Hematology-Oncology)

Dr Sunita Nasta has been working for a cure for lymphoma for over 20 years at the University of Pennsylvania Perelman School of Medicine. Patients and their families are the core of the battle. Working one patient at a time, she has taken her findings from the bedside back to her collaborators in the labs. From personalized diagnostics which find the specific mutations that drive lymphoma to the deficits that prevents the immune system from reacting to cancer to the challenges of survivors, she has seen the landscape change. While the war is not won, she knows that  each battle fought is one step closer. She is also a regional/national expert in the management of patients with Castleman disorder and Histiocytic disorders.

Education and training

  • Medical School: Virginia Commonwealth University
  • Residency: Baylor College of Medicine/Texas Children's Hospital
  • Residency: Baylor College of Medicine - Ben Taub General Hospital
  • Fellowship: Baylor College of Medicine/Texas Children's Hospital
  • Fellowship: University of Texas - MD Anderson Cancer Center
  • Fellowship: University of Texas Hospitals

What my patients think about me

Average Rating
5.0

823 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

May 2025
5.0
5.0
great doctor!
May 2025
5.0
5.0
outstanding
May 2025
5.0
5.0
she listens to you
May 2025
5.0
5.0
she is awesome

Insurance accepted

My Locations

Learn about location

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Nasta is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Ward RE, Dave N, Pai EL, Colbourn R, Banihashemi A, Nasta SD, Babatunde VD. Methotrexate-associated Peripheral Neuropathy on 18F-FDG PET/CT and MRI Masquerading as Neurolymphomatosis. , Clin Nucl Med. : 2025 ,Online ahead of print.

Elghawy O, Sussman JH, Yang AG, Thomas CJ, Carter JS, Landsburg DJ, Svoboda J, Kim E, Rook AH, Chung J, Plastaras JP, LaRiviere M, Hubbeling H, Chelius M, Nasta SD, Chong EA, Schuster SJ, Barta SK. Pembrolizumab in Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome. , JAMA Dermatol.: 2025 ,e250251

Potluri VS, Zhang S, Schaubel DE, Shaikhouni S, Blumberg EA, Nasta SD, Bloom RD, Cruz-Peralta M, Mehta RB, Lavu NR, Getachew B, Tandukar S, Reese PP, Puttarajappa CM. The Association of Epstein-Barr Virus Donor and Recipient Serostatus With Outcomes After Kidney Transplantation : A Retrospective Cohort Study , Ann Intern Med., 178(2): 2025 ,157-166

Svoboda J, Landsburg DJ, Gerson J, Nasta SD, Barta SK, Chong EA, Cook M, Frey NV, Shea J, Cervini A, Marshall A, Four M, Davis MM, Jadlowsky JK, Chew A, Pequignot E, Gonzalez V, Noll JH, Paruzzo L, Rojas-Levine J, Plesa G, Scholler J, Siegel DL, Levine BL, Porter DL, Ghassemi S, Ruella M, Rech A, Leskowitz RM, Fraietta JA, Hwang WT, Hexner E, Schuster SJ, June CH. Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure. , N Engl J Med. , 392(18): 2025,1824-1835

Canty EA, Broderick L, Flaherty D, Xavier M, Nasta SD, Dajani L, White AA. First reported case of a spontaneous and healthy pregnancy in a woman with persistent CAR T-cells 5 years after treatment for diffuse large B-cell lymphoma. , J Immunother Cancer. , 13(4): 2025,e011092

Ni V, Nasta SD, Barta SK, Schuster SJ, Chong EA, Svoboda J, Morrissette JJD, Barlev A, Bagg A, Priore SF, Landsburg DJ. Identification of a clinicopathologic prognostic index for newly diagnosed large B-cell lymphoma patients treated with R-CHOP. , Haematologica, 110(4): 2025,1023-1027

Pierson SK, Brandstadter JD, Torigian D, Bagg A, Lechowicz MJ, Alapat D MD, Casper C, Chadburn A, Chandrakasan S, Dispenzieri A, Fosså A, Hoffmann C, Ide M, Kurzrock R, Mukherjee S, Nasta SD, Navarro JT, Noy A, Oksenhendler E, Sarmiento Bustamante M, Shyamsundar S, Streetly MJ, Wong RSM, Zhang L, Lim MS, Srkalovic G, van Rhee F, Fajgenbaum DC. Characterizing the heterogeneity of Castleman disease and oligocentric subtype: Findings from the ACCELERATE registry. , Blood Adv.: 2025

Elghawy O, Wang J, Leung OJ, Swami N, Carvajal V, Yang G, Landsburg DJ, Svoboda J, Nasta SD, Chong EA, Schuster SJ, Thomas CJ, Carter JS, Bagg A, Barta SK. Clinical Impact of Next-Generation Sequencing of T-Cell Lymphomas: A Single Institution Experience. , Clin Lymphoma Myeloma Leuk., S2152-2650(25): 2025,35-7

Maillie L, Nasta SD, Svoboda J, Barta SK, Chong EA, Garfall AL, Gill SI, Porter DL, Schuster SJ, Catania C, Frey NV, Landsburg DJ. Prolonged Neurologic Symptoms Following Immune Effector Cell-Associated Neurotoxicity Syndrome in Patients With Large B Cell Lymphoma Treated With Chimeric Antigen Receptor-Modified T Cell Therapy. , Transplant Cell Ther., S2666-6367(25): 2025

Nikita K. Dave, Veronica Carvajal, Alex C. Watts, Jordan S. Carter, Michael Cook, Colin Thomas, Donald E. Tsai, Stephen J. Schuster, James N. Gerson, Stefan K. Barta, Jakub Svoboda, Elise A. Chong, Wei-Ting Hwang, Daniel J. Landsburg, Sunita D. Nasta Outcomes at a Single Institution with MTR Induction and Consolidation in the Management of Primary CNS Lymphoma , Blood Neoplasia: 2025